Streamlined analytical strategy using resonance Rayleigh scattering signal amplification for nanoscale quantification of rasagiline in tablets with content assessment.

Rasagiline (RSG), a prevalent drug for Parkinson's disease, is classified as a monoamine oxidase inhibitor. These drugs operate by elevating dopamine levels in the brain, with the objective of alleviating symptoms related to the illness. This work utilized a sensitive and feasible experimental approach to assess the amount of RSG. An experiment in a single pot, which is compatible with green chemistry, was used. The fundamental premise of this approach was the molecular-size-dependent resonance Rayleigh scattering phenomenon, arising from an association between the dual complex of Erythrosine and RSG. The combination of RSG medicine and Erythrosine in an acidic environment resulted in the formation of an association complex, which amplified the resonance Rayleigh scattering (RRS) signal. The increase in signal was directly associated with the concentration of RSG, particularly within the range of 50-1400 ng/mL. The amplification of the RRS signal was observed at a wavelength of 354 nm. Determining the limit of detection at 15.18 ng/mL and the limit of quantitation at 46 ng/mL demonstrated the method's sensitivity. The method's attributes were meticulously examined and refined. The methodological approach was validated in compliance with the International Council for Harmonisation (ICH) requirements to verify its dependability. Moreover, the approach was effectively utilized to assess RSG in its designated dose form. The utilization of existing RRS innovation to assess the target drug was extend to estimate content homogeneity was an impressive accomplishment. Clinical trial number: Not applicable.